ThermoGenesis Holdings (ThermoGenesis Holdings) Change In Working Capital : $1.99 Mil (TTM As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings Change In Working Capital?

ThermoGenesis Holdings's change in working capital for the quarter that ended in Dec. 2023 was $-0.61 Mil.

ThermoGenesis Holdings's change in working capital for the fiscal year that ended in Dec. 2023 was $1.99 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

ThermoGenesis Holdings Change In Working Capital Historical Data

The historical data trend for ThermoGenesis Holdings's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Change In Working Capital Chart

ThermoGenesis Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

2.13

-8.18

-1.72

-0.83

1.99

ThermoGenesis Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															0.43	0.51	0.85	1.24	-0.61

ThermoGenesis Holdings Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.99 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

ThermoGenesis Holdings Change In Working Capital Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ThermoGenesis Holdings (ThermoGenesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (NAS:THMO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

THR:Germany

Address

2711 Citrus Road, Rancho Cordova, CA, USA, 95742

Website

https://www.thermogenesis.com

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.

Executives

Xiaochun Xu	director	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu	director	2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu	director	2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph	director	MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford	director	7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate	director	350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble	officer: Principal Accounting Officer	2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu	director
Boyalife Investment Inc.	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545